A THESIS SUBMITTED TO
THE GRADUATE SCHOOL OF NATURAL AND APPLIED SCIENCES
OF ÇANKIRI KARATEKİN UNIVERSITY

INVESTIGATION OF THE EFFECTS OF SOME SCHIFF BASES AND SCHIFF BASE METAL COMPLEXES ON ALPHA-GLUCOSIDASE ENZYME ACTIVITY

IN PARTIAL FULFILLMENT OF THE REQUIREMENTS
FOR
THE DEGREE OF MASTER OF SCIENCE
IN
CHEMISTRY

BY

AYOOB HASAN JWAIR JWAIR

ÇANKIRI

2022

INVESTIGATION OF THE EFFECTS OF SOME SCHIFF BASES AND SCHIFF BASE METAL COMPLEXES ON ALPHA-GLUCOSIDASE ENZYME ACTIVITY

By Ayoob Hasan Jwair JWAIR

May 2022

We certify that we have read this thesis and that in our opinion it is fully adequate, in scope and in quality, as a thesis for the degree of Master of Science

Advisor **:** Assoc. Prof. Dr. Şevki ADEM

Examining Committee Members:

Chairman **:** Prof. Dr. Volkan EYÜPOĞLU
Chemistry
Çankırı Karatekin University

Member **:** Assoc. Prof. Dr. Ebru AKKEMİK
Food Engineering
Siirt University

Member **:** Assoc. Prof. Dr. Şevki ADEM
Chemistry
Çankırı Karatekin University

Approved for the Graduate School of Natural and Applied Sciences

Prof. Dr. İbrahim ÇİFTÇİ
Director of Graduate School

I hereby declare that all information in this document has been obtained and presented in accordance with academic rules and ethical conduct. I also declare that, as required by these rules and conduct, I have fully cited and referenced all material and results that are not original to this work.

Ayoob Hasan Jwair JWAIR

ABSTRACT

INVESTIGATION OF THE EFFECTS OF SOME SCHIFF BASES AND SCHIFF BASE METAL COMPLEXES ON ALPHA-GLUCOSIDASE ENZYME ACTIVITY

Ayoob Hasan Jwair JWAIR

Master of Science in Chemistry

Advisor: Assoc. Prof. Dr. Şevki ADEM

May 2022

α-glucosidase is an important target enzyme in the fight against type 2 diabetes. With its inhibition, the conversion of monosaccharides to monosaccharides slows down and their rate and rate of mixing into the blood decreases. In this study, it was aimed to investigate the effects of some Schiff bases and Schiff base metal complexes on alpha-glucosidase enzyme activity in vitro and in silico. The α-glucosidase enzyme activity was measured spectrophotometrically at 408 nm. Docking studies were carried out using the Molegro Virtual Docker program. 2D interaction details were determined using the Discovery Studio 2021 Client program. In the study, no inhibition effect was detected on the enzyme activity of ligands. The copper complexes of the ligands exhibited a very strong inhibitory effect. Strong inhibition effects have been detected in palladium complexes. Docking studies have shown that hydrogen bonds, hydrophobic and wan der Waals interactions are effective in the interaction of the molecular with the active site of the enzyme.

2022, 40 pages

Keywords: Type 2 diabetics, Alpha-glucosidase, Enzyme activity, Schiff base

ÖZET

BAZI SCHIFF BAZLARININ VE SCHIFF BAZ METAL KOMPLEKSLERİNİN ALFA-GLUKOZİDAZ ENZİM AKTİVİTESİ ÜZERİNE ETKİLERİNİN İNCELENMESİ

Ayoob Hasan Jwair JWAIR
Kimya, Yüksek Lisans
Tez Danışmanı: Doç. Dr. Şevki ADEM
Mayıs 2022

α –glucosidase tip 2 diyabet ile mücadelede önemli bir hedef enzimdir. Onun inhisbisyonu ile monosakkaritleri mono sakkaritlere dönüşümü yavaşlar ve kana karışma hızları ve oranı düşer. Bu çalışmada bazı schıff bazlarının ve schıff baz metal komplekslerinin alfa-glukozidaz enzim aktivitesi üzerine etkilerinin in vitro ve in silico olarak incelenmesi amaçlanmıştır. α –glucosidase enzim aktivitesi 408 nm'de spektrofotometrik olarak ölçülmüştür. Docking çalışmaları Molegro Virtual Docker programı kullanılarak gerçekleştirilmiştir. 2D etkileşim detayları Discovery Studio 2021 Client progamı kullanılarak belirlendi. Yapılan çalışmada ligandların enzim aktivitesi üzerinde herhangi bir inhibisyon etkisi tespit edilmemiştir. Ligandların bakır kompleksleri çok güçlü bir inhbitör etkisi sergilemiştir. Palladyum komplekleride güçlü inhibisyon etkileri tespit edilmiştir. Docking çalışmaları, molekülerin enzimin aktif bölgesi ile etkileşiminde, hidrojen bağlarının, hidrohobik ve wan der Waals etkileşimlerinin etkili olduğunu göstermiştir.

2022, 40 sayfa

Anahtar Kelimeler: Tip 2 diyabet hastaları, Alfa-glukosidaz, Enzim aktivitesi, Schiff bazı

PREFACE AND ACKNOWLEDGEMENTS

I would like to thank my thesis advisor, Assoc. Prof. Dr. Şevki ADEM, for his patience, guidance and understanding.

I also thank who brought me to this level of knowledge, My mother and my father.

I also thank who supported my efforts throughout my study days, My wife Marwa Jamal.

and thanks for all.

Ayoob Hasan Jwair JWAIR
Çankırı-2022

CONTENTS

LIST OF SYMBOLS

°C	Celsius
µL	Microlitre
µM	Micrometre
3D	Three dimensional
IC_{50}	Half-maxımal ınhıbıtory concentratıon
mL	Millilitre
mM	Millimolar
mmol/L	Millimoles per litre
nm	Nanometre
α	Alpha

LIST OF ABBREVIATIONS

ADA	American diabetes association
AGIs	Alpha-glucosidase inhibitors
DPP-4	Dipeptidyl peptidase 4
FBG	Fasting blood glucose
GLP-1	Glucagon-like peptide-1
HbA1c	Hemoglobin A1c
PBG	Postprandial blood glucose
T2DM	Type 2 diabetes mellitus
UKPDS	United kingdom prospective diabetes study
ULN	Upper limit of normal
US FDA	United States Food and Drug Administration
WHO	World health organization

LIST OF FIGURES

LIST OF TABLES

1. INTRODUCTION

Type 2 diabetes-induced hyperglycemia may be treated with more than a dozen medications that have been given the green light by the FDA (Gourgari *et al.* 2017). The process by which each class works to reduce blood glucose levels is distinct. There are oral anti-hyperglycemic medications (AGIs) that inhibit intestinal alpha-glucosidase by competing and reversibly inhibiting the enzyme. Poly- and disaccharide carbohydrates are broken down into glucose by these enzymes in the upper gastrointestinal tract (Bischoff 1995). The slowing of postprandial blood glucose rises may be achieved by inhibiting this enzyme (PBG). Acarbose, miglitol, and voglibose have all been licensed for the treatment of type 2 diabetes by a variety of national drug regulatory agencies. Two of them (acarbose and miglitol) are now available in the United States. It is possible to employ the AGIs alone or as part of a larger treatment plan. The average decrease in hemoglobin A1c (HbA1c) while using monotherapy is 0.8 percent (Laar *et al.* 2005). HbA1c decreases are proportional to the initial HbA1c level. If the HbA1c level is higher (>9%), the effect is greater (0.93 percent), but when the HbA1c level is lower (0.56 percent percent), the impact is reduced (7 percent). In the first hour, the 1 hour PPG drops by 2.32 mmol/L and the fasting blood glucose (FBG) drops by 1.09 mmol/L. In this case, hypoglycemia is not an issue, and weight gain is minimal to nonexistent. Most common gastrointestinal adverse effects are diarrhoea, stomach cramps, and flatulence, which are all dose-dependent. Because of the several daily dosages required and the poor tolerability, AGIs are still seldom administered in the United States and the UK. As a result of the East Asian diet's high carbohydrate content, this class is more popular in Asia, notably China (Zhu *et al.* 2013).

Diabetic type 2 is a major cause of death and disability across the globe and a significant public health issue in the twenty-first century. Diabetic mortality are expected to rise by more than 80% in the next several decades, according to the World Health Organization (WHO) (World Health Organization November 2008). Because of this, there will be an ever-increasing need for medical treatment in type 2 diabetes. In order to lessen the likelihood of type 2 diabetes-related long-term health consequences,

glucose management is an essential objective. An key target for diabetes control is alpha-glucosidase inhibition, which is one of the most potent therapies. In the case of alpha-glucosidase, carbohydrates are broken down into simple sugars that may be absorbed from the gut. In people with type 2 diabetes, alpha-glucosidase inhibitors are used to improve glycemic control after meals because they minimize the impact of carbohydrates on blood sugar. The brush border of the small intestine is where enzymes like alpha-glucosidase are blocked by these saccharides. An enzyme found on the membrane of the small intestine, alpha-glucosidases hydrolyze oligo-, trisaccharides, and disaccharides into glucose and other monosaccharides (Manohar *et al.* 2008). In addition to membrane-bound alphaglucosidases, it also inhibits pancreatic alpha-amylase. In the small intestine, pancreatic alpha-amylase breaks down complex starches into oligosaccharides. Carbohydrate digestion is impeded when specific enzyme systems are inhibited. In order to use less glucose, carbohydrates are not broken down into glucose molecules. These pharmacological regimens have a short-term impact of lowering blood glucose levels in diabetics and a long-term effect of slightly decreasing hemoglobin levels. Using an in silico technique, this research looked for the alpha glucosidase activity of Sesamin and its derivatives to detect the drug's effects on type 2 diabetes.

To prevent glucose absorption, AGIs must interact with carbs near enzyme action, where their nitrogen component acts as a competitive inhibitor. All AGIs work by blocking -glucosidase enzymes at the brush border of the upper small intestine. Different -glucosidase inhibitory actions may explain for disparities in the occurrence of adverse consequences. This is the case with AGI (acarbose), which inhibits glucoamylase, sucrase, maltase and dextranase (Hanefeld *et al.* 2007). As an alternative, it blocks alpha-amylase while allowing beta-glucosidases to function normally. It is more effective in inhibiting disaccharide-digesting enzymes like sucrase and maltase than acarbose, but it does not block alpha-amylase as acarbose does (Junge 1996). As a pseudo monosaccharide, it has a weak interaction with the sodium-dependent glucose transporter in the gut (Joubert *et al.* 1990). Type 2 diabetes patients have shown that alpha-glucosidase inhibitors are safe and effective, and the lack of cardiovascular risk is encouraging in this condition. Hyperglycemia after meals, high blood pressure, rapid

glucose fluctuations, and obesity appear to be less of a concern as well. Hypoglycemia, a known risk factor for cardiovascular death, is almost nonexistent with this treatment, in contrast to conventional methods of reducing blood glucose. Researchers have found that (Standl *et al.* 2012).

If alpha-glucosidase inhibitor overdose occurs, there should be no special treatment required (Spiller and Sawyer 2006). In spite of the ease with which glucose silo inhibitors can be administered alongside insulin, sulfonylurea, or metformin, breakthroughs in the treatment of type 2 diabetes have been made decades after AGIs were first used, due to the risk discrepancies of AGIs like acarbose-induced liver damage caused by long-term use (American Diabetes Association 2012). However, Miglitol seems to represent no substantial risk of liver damage (Vega *et al.* 2000), which is contrary to the findings of the previous studies. Individuals with documented diabetic ketoacidosis, sensitivity to the drug or inflammatory bowel illness, partial intestinal blockage, colonic ulcers, or patients vulnerable to intestinal obstruction should not take alpha-glucosidase inhibitors (Scott and Spencer 2000). People who have severe digestion or absorption issues, as well as those whose symptoms might be exacerbated by an increase in intestinal gas production, should avoid taking them. Some patients are unable to tolerate AGIs, which is why researchers are continually working on newer AGIs. Finding active compounds from existing chemicals is hence the first and most important step in AGIs drug development process. Spectroscopic and molecular analysis may be completed in a matter of days using virtual screening; when a chemical compound has been selected, it is submitted to spectroscopy and molecular analysis.

2. LITERATURE REVIEW

2.1 Inhibitors of Alpha-Glucosidase

Metformin, according to some studies, is the first-line treatment for (T2DM) management (Garber et al. 2013). The most widely accepted treatment for hyperglycemia is monotherapy with metformin (International Diabetes Federation 2012). People with T2DM who use Metformin may experience worsening of their gastrointestinal problems, making it an unwise choice. Metformin, as well as "sulfonylurea, meglitinide, or dipeptidyl peptidase 4 DPP-4 inhibitor," should not be used by patients at risk of renal dysfunction or other disorders that may contribute to renal dysfunction, according to the European Association for the Study of Diabetes. According to (Inzucchi et al. 2012) (Inzucchi and colleagues 2012), The American Association of Clinical Endocrinologists recommends glucagon-like peptide-1 GLP-1 agonists, alpha-glucosidase inhibitors, DPP-4, sulfonylurea, and GLP-1 as viable metformin alternatives for persons who desire to reduce weight. So, what are AGIs and how do they operate, as defined by various works of fiction? T2DM was allowed to be managed by AGIs in the 1990s (Stein *et al.* 2013). Each alpha-glucosidase inhibitor has the following properties. Structures that resemble sugar. It is possible to build ionic and hydrogen bonds with residues that catalyze nucleophilic reactions. Structures resembling transitional states. Ionic and hydrophobic interactions may occur at locations other than the active site. Having an epoxy or aziridine group that may bind to enzymes. (Hakamata *et al.* 2009). AGIs are an oral antihyperglycemic medication class that works by inhibiting intestinal alpha-glucosidase in a competitive and reversible manner to treat and mitigate type 2 diabetes (International Diabetes Federation 2012). These studies (Hedrington and Davis 2019) shown that inhibiting these enzymes helps manage blood sugar levels by lowering PPG (plasma protein G). There are three AGIs that have been approved for drug regulation by various national authorities: acarbose, miglitol, and voglibose. AGIs may be used alone or in conjunction with other treatments. Haemoglobin A1C (hba1c) levels decreased by 0.8% when the drug was administered alone. Since the beginning, the drop in HbA1c has been equal to the rise. Higher baseline HbA1c levels have a 0.93 percent effect, whereas lower baseline HbA1c levels

have a 0.56 percent impact. There is an average decline of 1.09 mmol/L in FBG and a reduction of 2.32 mmol/L in PPG after one hour. Among Asian countries, particularly China, AGIs tend to have a greater potential to cure Type 2 Diabetes (T2DM), which may be a result of the carbohydrate-rich diet in the region. The most successful medications for PPHG are Acarbose, Voglibose, and Miglitol, therefore what are the most important clinical results from their administration.

These alpha-glucosidase inhibitors, or reversible inhibitors of alphaglucosidase, a small intestine enzyme, are one therapy option for type 2 diabetes. Post-prandial glucose peaks are prevented, and insulin levels are lowered, since complex carbohydrate absorption is delayed. Acarbose, miglitol, voglibose, and emiglitate are the four alpha-glucosidase inhibitors on the market at the present time. Acarbose is the most often recommended of them. Treatment objectives aren't being fulfilled, or there are contraindications to other drugs, thus it's often used in conjunction with other diabetic treatments in most nations. Patients with isolated high postprandial glucose peaks may benefit from alpha-glucosidase inhibitors because of their particular method of action. In addition, alpha-glucosidase inhibitors may have a favorable impact on postprandial hyperinsulinaemia, a possible risk factor for macrovascular disease. Further beneficial effects on hypertriglyceridemia have been shown (Reaven 1990). The most common adverse effects of alpha-glucosidase inhibitors are flatulence, diarrhoea, and stomach soreness. Unlike other hypoglycaemic medications, these ones do not have any negative effects.

Several studies have shown that AGI use may cause liver damage, however the results are inconsistent. We conducted a systematic review and meta-analysis to examine the risk of hepatotoxicity related with the use of AGIs in patients with type 2 diabetic mellitus (T2DM). A total of 2881 individuals from 14 RCTs met the criteria for inclusion. It is statistically significant that AGIs therapy differed significantly from controls in those patients who had abnormally high AST and ALT levels (OR 6.86, 95% CI 2.50 to 18.80; OR 6.48, 95% CI 2.40 to 17.49). (ULN). In various subgroups, increases in AST and ALT levels that exceeded 1.8 times the upper limit of normal (ULN) had varying outcomes (AST: OR 0.38 vs 7.31; interaction P=0.003; ALT: OR

0.32 vs 4.55; interaction p=0.02). In the meta-analyses, higher doses of AGIs were connected to an increased risk of hepatotoxicity. analysis's The use of surrogate measures was not connected with any clinically relevant adverse effects (i.e. ALT and AST). Patients in Asia are often prescribed oral hypoglycemic drugs known as AGI (alpha-glucosidase inhibitors). As a potential first-line therapy or in conjunction with other antihyperglycemic medications, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) propose AGIs. 4 if required (Yang *et al.* 2014).

As with other regularly used anti-diabetic medications, AGIs have shown to be equally effective5–7. Acarbose was shown to be as effective as metformin in the treatment of newly diagnosed type 2 diabetes, according to a recent comprehensive study1. AGIs do not promote weight gain, hypoglycemia is infrequent, and drug-drug interactions are minimal1,7,8. AGIs, on the other hand, have been linked to a variety of uncommon but serious hepatic side effects9–11 and have been shown to raise liver enzyme levels12–18. This association has yet to be demonstrated, and the extent of its influence on liver enzyme levels is yet unknown. As liver adverse events are very rare, individual studies are unable to answer these key clinical questions. Consequently, these investigations are unable to address these critical clinical issues. Meta-analyses, which combine the results of many studies, may allow researchers to discover a subtle but clinically significant difference. The link between hepatotoxicity and AGIs was examined in a review that included randomised controlled trials as well as other types of investigations. Hepatotoxicity was expected to be more common in AGIs than in those with no usage (Li *et al.* 2014).

2.2 Presently Available Proof Results of AGI's Adminstration Study

Randomized studies have been conducted to determine if alphaglucosidase inhibitors alone or in conjunction with other medications are effective. Acarbose is usually evaluated for its efficacy. Glycosylated haemoglobin decreased by 0.6 percent in a significant clinical investigation compared to placebo (Coniff *et al.* 1995). Acarbose and sulphonylurea were shown to reduce HbA1c by 1.0 and 1.4 percent, respectively, in the

same clinical research. Acarbose, an oral antidiabetic medication, and insulin therapy were compared as part of the United Kingdom Prospective Diabetes Study (UKPDS) (Holman *et al.* 1999). 1946 The three-year research comprised a large number of participants. The study drug was still being used by 39% of patients in the acarbose group and 58% of patients in the placebo group after three years. Over a period of three years, acarbose reduced glycosylated haemoglobin by 0.2 percent compared to placebo ($p=0.003$). There was a 0.5 percent difference when only patients who continued to take the trial drug were taken into account. Similar findings were seen for both fasting and postprandial glucose levels. Clinical significance of this reduction in glycosylated haemoglobin remains unclear, particularly when considering that for most patients, glycated haemoglobin was still greater than 8.0% in the per-protocol study. Furthermore, this research lacked information on patient-related outcomes including mortality and morbidity. Consequences of taking the drug were diarrhoea, abdominal pain, and flatulence, all of which subsided quickly. Acarbose has been the subject of a few reviews (Scheen 1998), some of which are included here. According to their literature search, inclusion criteria for literature, and quality assessment, they were not done in an organized way. None of the reviews included a meta-analysis. Alpha-glucosidase inhibitors will be evaluated against placebo or any other medication in randomized controlled trials for their efficacy on type 2 diabetes mellitus. For this research, we'll examine glycated haemoglobin, fasting, postprandial, and lipid levels, as well as body weight and lipid composition.

New trials that may be relevant to the review will be added on a regular basis. Alpha-glucosidase inhibitors have a poorer effect on decreasing blood glucose levels than most other OHAs, according to the three currently available inhibitors. There are several studies that support this conclusion (Cheng and Fantus 2005) Compared to placebo, clinical studies have indicated an average reduction in hemoglobin A1c of roughly 0.5% to 1.0%. (Inzucchi 2002). Not surprisingly, PPG levels have risen higher than fasting levels, which is not surprising (Lebovitz 1997). In addition, it was found that triglyceride levels had decreased somewhat (Bayraktar *et al.* 1996). Glycemic control seems to affect how much fasting and postprandial plasma glucose contribute to HbA1c levels (Monnier and Colette 2009). The importance of PPG in glycemic management

increases when HbA1c levels fall. Normal FPG and HbA1c levels do not protect against the negative effects of elevated PPG levels on glycemic management and cardiovascular events (Ning et al. 2010). Since the therapy of (PPHG) to reduce the risk of cardiovascular events in T2DM patients has become an important research topic (Joshi et al. 2015).

Postprandial hyperglycemia may be treated most effectively with (Acarbose, Voglibose, and Miglitol). It is still best to avoid using AGIs in those who have digestive system problems. The prevalence of side effects like flatulence and diarrhea makes this an unwise choice (Chiniwala and Jabbour 2011). AGIs inhibitors are seldom utilized on their own because of their limited efficacy in comparison to other OHAs. The first-line therapy for moderate to severe hyperglycemia (9.0 percent) is not advised with these medications (Canadian Diabetes Association and Cheng 2013). When paired with other OHAs, AGIs are regarded as the most potent. Starting at 25 mg once a day and gradually increasing to 100 mg three times a day is the recommended starting point. However, side effects on the digestive system limit the dose to 50 mg (Cheng and Fantus 2005). We need to find ways to utilize AGIs in monotherapy without causing as many adverse effects and with the least amount of daily dose as feasible due to these restrictions on their use. Sulfonamides and its derivatives are the most promising candidates for diabetic treatment discovery and development since they are well-known and can be further developed and tested. This thesis, however, aims to know what makes sulfonamides so promising.

AGIs have been tested in clinical studies with placebos and/or active control. They have all been shown to be more effective than a placebo (Laar *et al.* 2005). PPG reductions have been larger in trials comparing AGIs to other oral antihyperglycemic medications. HbA1c and FPG levels did not seem to differ significantly between the two oral treatments (Pan *et al.* 2009). Also shown in clinical studies is an improvement in postprandial hyperinsulinemia (acarbose and voglibose) (Vichayanrat *et al.* 2002). When insulin levels are reduced after meals, hepatic lipogenesis and triglyceride absorption are inhibited (Kado *et al.* 1998). Acarbose has been demonstrated to indirectly and positively alter beta-cell activity by decreasing PPG and reducing glucose

toxicity (Laube *et al.* 1998). According to certain studies, AGIs have also been shown to boost GLP-1 levels, which may possibly have a role in reducing PPG. The amounts of nitric oxide and nitric oxide synthase were found to have increased significantly over time (Zheng *et al.* 2013). A group of Japanese T2DM patients studied by (Narita *et al.* 2009) found that miglitol reduced stomach inhibitory polypeptide responses.

AGIs have been studied in combination with other oral antihyperglycemic medications in a number of randomized placebo-controlled studies in people with type 2 diabetes (Rosak *et al.* 2022). An current oral antihyperglycemic medication benefits greatly from the addition of an AGI. An increased HbA1c, FPG, and PPG decrease was shown when metformin and acarbose were used together. Metformin and Miglitol were equally efficacious when used together. Combination therapy's benefits have been shown to last for at least five years in long-term trials (Mertes et al. 2001). There have been studies using AGIs in conjunction with sulfonylurea (Rosak *et al.* 2022), dipeptidyl peptidase-4 inhibitors (Takahara *et al.* 2014), thiazolidinediones and basal insulin that have had similar positive outcomes. Acarbose has been studied in 192 diabetics over the age of 60. PPG (2.1 mmol/h/l) and mean FPG (0.7 mmol/l) decreased considerably more in the acarbose group than in the placebo group after a 12-month treatment period. Those receiving acarbose also saw a substantial decrease in their relative insulin resistance (0.8). There were no reports of hypoglycemia or other adverse reactions to the medication. There is no danger of hypoglycemia or toxicity if AGIs are not taken in conjunction with insulin or sulfonylureas. Flatulence, diarrhea, and stomach pain are the most prevalent side effects of AGIs. Compared with other members of the group, Voglibose seems to be less effective Acarbose substantially reduced PPG more than voglibose in a head-to-head randomized experiment (Vichayanrat *et al.* 2002). PPG was significantly reduced in another trial when subjects switched from voglibose to acarbose (Matsumura *et al.* 2009). For type 2 diabetes, studies have demonstrated that miglitol is superior than acarbose and voglibose in reducing blood glucose fluctuations and inflammation-inducing gene expression.

While AGI is more successful and tolerated in Asia than in the West (Cambodia and China among others), this is not always the case in the West. A meta-analysis of 10

non-interventional studies found that acarbose was more beneficial in Southeast and Southern Asians than in European Caucasians or Asians from the east, southeast, and south (Weng *et al.* 2015). Acarbose was shown to be effective and well tolerated in an uncontrolled research in Indians with type 2 diabetes (GlucoVIP) (Philip *et al.* 2013). Eighty-eight percent of those who took the medication said it was "excellent" or "very good" in terms of tolerability. More than 97% of individuals sustained acarbose medication following the research. The carbohydrate composition of Eastern and Western diets differs greatly, which may account for the ethnic differences in the class's effectiveness. Meta-analysis of 46 studies found that acarbose was significantly more effective (p 0.0001) than placebo or other antihyperglycemic drugs in T2DM patients who ate an eastern diet (Zhu *et al.* 2013).

2.3 AGIs' Role in Modern Treatment Approaches. Comparative Analysis if the Different Oral Blood Glucose Lowering Medications

On the topic of hyperglycemia treatment, in 2006, the American Diabetes Association and the European Association for the Study of Diabetes released a "consensus statement." To maintain a GHb of 7 percent or below, it is recommended that patients take metformin along with a lifestyle modification, followed by either a thiazolidinedione (TZD), sulphonylurea, or insulin. Treatment does not involve AGIs, but it is indicated that "appropriate choice in chosen patients" is a "appropriate option" (Nathan *et al.* 2006). The British National Institute for Clinical Excellence (2002) suggests beginning an oral pharmacological regimen when a lifestyle change has been unsuccessful. If metformin is contraindicated or if metformin treatment fails, sulphonylurea should be used as an alternative or supplement to metformin. If metformin is not working or if a sulphonylurea plus metformin combination is not working, TZDs should be added. In those who are unable to use oral medications to decrease their blood sugar, AGIs may be an option.

Recommendations from the Dutch College of General Practitioners (DCGP) have been updated lately. As an alternate therapy for DM2 in the past, acarbose was recommended in the case that either sulphonylurea or metformin failed or was contraindicated. There

is no longer any recommendation for Acarbose, the sole AGI available in the Netherlands (Rutten *et al.* 2006). With established cardiovascular disease, but without an increased risk of heart failure, TZDs are included in the advice for obese patients (BMI 27 kg/m2) with metformin ineffectiveness. AGIs have been ranked low in all of these recommendations, which indicates that there is sufficient evidence to support the superiority of the other oral medications. Metformin seems to have a solid case: studies comparing it to sulphonylurea or insulin indicated that it reduced mortality and had beneficial effects on diabetes-related morbidity (Anonymous 1998a). Furthermore, meta-analyses have shown that metformin reduces HbA1c by 0.9 percent (Johansen 1999) or 1.0 percent compared to placebo. Sulphonylurea and TZDs have weaker arguments in their favor. Strict glycemic control, not sulphonylurea's effects, are likely to be responsible for the beneficial effects on microvascular problems found in individuals on either the medication or insulin (Anonymous 1998b). A benefit on diabetes-related mortality or macrovascular morbidity has yet to be discovered for sulphonylurea, according to the research done to far. Sulphonylurea, on the other hand, has remained under investigation for its possible negative impact on cardiovascular health, despite the University Group Diabetes Program's findings that tolbutamide usage raised the incidence of cardiovascular morbidity (Goldner *et al.* 1971). Sulphonylureas may also cause dangerous hypoglycemia episodes that can be fatal. Prescription medicine costs in the Netherlands rose from just over 2 million Euros in 2001 to over 24 million Euros in 2005 as the number of Dutch persons using TZD increased. Pioglitazone significantly reduced mortality, nonfatal myocardial infarction, and cerebrovascular accident in obese people with DM2 and known cardiovascular morbidity when compared to placebo (Dormandy *et al.* 2005). However, the conclusions of the Cochrane systematic review need to be verified. Pioglitazone has been demonstrated to reduce mortality and morbidity in a thorough assessment of 22 studies. PROACTIVE's findings are intriguing despite this. Rosiglitazone, another TZD, was shown to increase the risk of myocardial infarctions and cardiovascular mortality in a meta-analysis (Nissen and Wolski 2007). This cautious approach is supported by these findings. Due to the potential of fluid retention, TZDs are not recommended for patients with heart failure. The results of AGI therapy are less harmful than one would assume given the existing guidelines for AGIs. Indirect comparisons show that AGIs had a 0.1

percent lower effect on Ghb than metformin, and a 0.2 to 0.4 percent lower effect than TZDs (Bolen *et al.* 2007). Post-load glucose control may be improved as well, however just one comparative study and no meta-analyses can substantiate this claim (Hoffmann and Spengler 1997). AGIs help people lose weight while also being safe, since there have been no reports of any negative side effects associated with their use. STOP-NIDDM study reveals that AGI may help reduce cardiovascular events in those with impaired glucose tolerance (Chiasson *et al.* 2003).

Despite the fact that the conclusions of this research have been extensively challenged, a retest is still required (Chiasson *et al.* 2004, Kaiser and Sawicki 2004). If a single research shows that Acarbose is useful for people with type 2 diabetes, it cannot be ignored because of publication bias, heterogeneity, detection bias, and confounding (Hanefeld 2004, Laar and Lucassen 2004). People with poor glucose tolerance (Holman et al. 1999, Laar 2008) and pre-diabetes are the focus of three recent clinical studies (Laar 2008). AGIs' gastrointestinal adverse effects, which are clinically significant, may hinder patient compliance. According to the Cochrane review, acarbose at a low dosage (50 mg tid) had equivalent effects on GHb and fewer side effects as the drug's double dose (100 mg tid) (Laar *et al.* 2005). More expensive costs and having to take medicine three times a day rather than once or twice a day may be additional downsides of using Sulphonylureas. Because it has comparable blood sugar control effects as metformin, has no known adverse side effects, reduces body mass index, and may lessen the risk of heart disease as a therapy for type 2 diabetes, an AGI is an attractive therapeutic alternative. Type 2 diabetes patients may find it an appealing therapeutic alternative because of the possibility of reducing the drug's adverse effects while yet maintaining its blood sugar management benefits. Pastes used in traditional Chinese cooking, such as touchi extract, have been demonstrated to block alpha-glucosidase and lower blood sugar levels. Using AGIs does not need taking them orally; they may be supplied as a dietary supplement or as "smart food" (Fujita *et al.* 2001).

2.4 AGIs in Individuals with Poor Glucose Tolerance or Low Fasting Blood Glucose Levels are a Common Finding

Impaired glucose tolerance (IGT) and impaired fasting blood glucose (IFBG) are two risk factors for the development of DM2 (and cardiovascular disease) (IFBG). Diabetic 2 syndrome (DM2) is a condition in which the body fails to maintain a normal level of glucose homeostasis. If you opt to address these disorders, diet and exercise are the first-choice treatments for improving glucose tolerance (Nathan *et al.* 2007). With lifestyle changes, a 58 percent decrease in the risk of developing type 2 diabetes may be accomplished (Tuomilehto *et al.* 2001). The use of pharmaceuticals to treat IGT and IFBG may raise ethical questions, since it might be seen as medicalizing the healthy. A small but growing body of research suggests that medicines that increase insulin sensitivity may be beneficial in the treatment of IGT and IFBG. RRR of 31% was found in studies using metformin, while RRR of 60% was found in studies using rosiglitazone (Gerstein *et al.* 2006).

2.4.1 Results of a Cochrane review on the use of AGIs in IGT and IFBG

Cochrane comprehensive review of studies found that patients with IGT or IFBG who were treated with acarbose, miglitol, or voglibose were less likely to develop type 2 diabetes, cardiovascular disease, serum lipid profile, blood pressure, body weight, and side effects (Laar *et al.* 2006).

On the other hand, we searched for any and all controlled trials that compared AGI monotherapy against any other medication. In all, there were five trials (2360 participants). Overshadowed by another large-scale investigation with a larger bias risk were the conclusions of this study (Chiasson *et al.* 2002). No meta-analyses were possible due to the lack of data. This study found that the risk of developing type 2 diabetes (RR 0.78, 95% confidence interval 0.68–0.90; NNT = 10) and cardiovascular events (RR 0.46, 95% confidence interval 0.26–0.86, NNT = 50) was reduced by acarbose. However, since this result was not the study's primary objective, more investigation is required to verify the findings.

2.4.2 Preventive methods and the role of AGIs

In the Cochrane research, acarbose was shown to reduce the risk of developing type 2 diabetes in persons with IGT. However, it isn't clear whether this is supposed to prevent diabetes or only delay its start. Since just 47 cardiovascular events were recorded in a single clinical study, this conclusion needs to be validated, but it did reveal a protective effect on the overall incidence of cardiovascular events. Not only that, but it was not designed from the start with that end in mind (Chiasson *et al.* 2003). Data from recently completed but unreported investigations (Holman *et al.* 1999) as well as data from continuing research will be accessible in the next years (Laar 2008). Lifestyle treatments are still more successful than AGIs in lowering the occurrence of DM2 (Ratner *et al.* 2005).

It remains to be seen whether medication treatments in persons who do not have any sickness or even feel unwell are desirable. Doctors in general practice are often faced with the physical repercussions of social issues like the widespread adoption of sedentary lifestyles or the feeling of personal loneliness and social exclusion. It's much like a banker who talks money when presented with an issue: A doctor will speak medicine even when dealing with an issue that's not medical. (Metzl and Herzig 2007) have emphasized the topic of medicalization in the 1970s, and it is still relevant today. Preventive therapies for DM2 were shown to be problematic in a focus group research with Welsh physicians and practice nurses (Williams *et al.* 2004). A solution to the dilemma of how to draw the line between the medical and social responsibilities of society, governments, schools, and the person will be impossible to come up with. What matters most in this philosophical and ethical debate is to pose the question in the first place.

3. MATERIALS AND METHODS

3.1 Materials

3.1.1 Equipments

- For detecting alkalinity and acidity, pH Meter with Glass Electrode and calibration solutions (HCl, NaOH) A centrifuge is used to prepare the substrate.
- Magnetic Hot Plate Stirrer for Preparation of Buffer.
- Solid material measurement and preparation using an analytical balance.
- Measurement of absorbance using a microplate spectrometer.

3.1.2 Regants

- Enzyme: Saccharomyces cerevisiae -glukosidase
- A p-nitrophenyl glucoside substrate
- Distilled Water with Sodium Phosphate as a Buffer

3.1.3 Preparing the Solution

Acidic and basic solutions were used to alter the pH of a buffer solution (20 mM sodium phosphate, pH 6.8 at 20°C) to the desired level.

In the assay buffer, enzyme was dissolved to a concentration of 0.0025 units, and then used in the experiment.

Input: 2 mM of the substrate In grams, the substrate was dissolved in a pH 6.8 buffer solution.

3.2 Methods

3.2.1 Disinhibiting qualities

Table 3.1 depicted the reaction combination. Enzyme activity was measured at five different sulfa Schiff base concentrations to investigate the inhibitory effects of substances. Solution of slope equation for activity % and final concentration of each sulfa Schiff base compound was used to calculate the IC50. In the absence of inhibitors, enzyme activity is recognized as a control.

Table 3.1 In the alpha-glucosidase activity test, the solution and its volume were employed

Solution	Volume (µL)
Buffer	100
Substrate	40
Enzyme	10
Distilled water	80
Temperature (^{o}C)	37
Wavelength (nm)	408

3.2.2 Moleculer docking

In the study of drug-receptor interactions, a method called molecular docking is often used. The outcomes of molecular docking are critical in determining how drugs interact with receptors. Drug candidates' molecules' activity and affinity may be estimated by estimating their binding orientation with their targeted targets using this method. t (Rahim *et al.* 2020). Molegro Virtual Docker was used to do the molecular docking method. Saccharomyces cerevisiae alpha-glucosidase was constructed using the crystal structure of oligo-1,6-glucosidase (3A4A), which has a 72 percent sequence identity with alpha-glucosidase (Liu *et al.* 2011). Processes such as these were carried out during the docking simulation The MVD tool was used to add hydrogen atoms to specific protein residues in the 3D structure. Molegro Virtual Docker's default settings resulted in significant energy savings. The sulfa Schiff base compounds' 3D models

were imported into MVD as (mol) files (Sochacka and Baran 2012). Quickly, MVD grid-based method identified the target cavity containing the active sites of the side residues. Cavity residues were kept to an absolute minimum. While minimizing, torsion angles of side chains were changed. However, torsional angles of amino acid side chains around the protein cavity were permitted to fluctuate while the target backbone remained rigid. All of the specified side chains were reduced in proximity to the docked ligand's indicated position. LIGAND energy decreased when side chains were being reorganized. Ordinary non-softened potentials were used to rearrange the side chains and decrease each ligand. In order to keep the docking search as simple as possible, all of the ligands' flexible torsions were made rigid throughout the docking run. Molecules in monoanionic and neutral states were docked to the cavity one at a time to create the complexes. Each complex was subjected to several iterations, each of which produced a single final solution (pose). Each cluster's lowest-energy docking result was presented, and comparable postures were omitted, leaving just the highest-scoring docking position. MolDock scores were used to rank the 10 newly obtained postures. Examining the postures using weighted reranking scores (Rerank Score) helped improve the ranking accuracy of the poses. For each complex, the posture with the lowest Rerank Score value was selected (Sochacka 2014).

4. RESULTS AND DISCUSSION

Several ligand complexes were generated and tested against -glucosidase inhibitory potential in vitro for α -glucosidase inhibitory activity. When compared to the reference medication acarbose (IC_{50} = 0.80 M), all analogues showed inhibition ranging from 0.300 to 7.617 µM. Two, four, and six of the series. Ligand complexes were not shown to be particularly potent inhibitors. There was some inhibitory action in 5, but it was not overwhelming. Weak inhibitory action was found in compounds 1 and 3. According to the IC_{50} values of each analogue, the inhibitory potential may be displayed in this order: Metal Pd(4MeOS1M), Pd(4MeOS2M) Pd(3MeOS2M), Cu(4MeOS1M), Cu(4MeOS2M), and Cu(3MeOS2M). Table 4.1 lists their half maximum inhibitory concentrations (IC_{50}).

Table 4.1 Compounds affect the activity of the enzyme α –glucosidase

	Compounds	Docking Code	IC_{50} values (µM)	MolDock Score	HBond
1	$Pd(3MeOS2M)_2$	Unknown 1_1	7.617	-192.885	-5.69457
2	$Pd(4MeOS1M)_2$	Unknown 1_3	0.436	-237.517	-6.17832
3	$Pd(4MeOS2M)_2$	Unknown 1_5	6.301	-227.692	-3.31061
4	$Cu(3MeOS2M)_2$	Unknown 1	0.358	-186.8	-8.5723
5	$Cu(4MeOS1M)_2$	Unknown 1_2	0.517	-229.596	-5.98616
6	$Cu(4MeOS2M)_2$	Unknown 1_4	0.300	-216.549	-6.43765
7	3MeOS2M		-		
8	4MeOS1M		-		
9	4MeOS2M		-		

The area chosen for docking investigations, as shown in Figure 4.1.



Figure 4.1 Structure and docking region of α –glucosidase

By inhibiting the α –glucosidase enzyme, this $Pd(3MeOS2M)_2$ molecule was shown to work. Figures 4.3 and Figure 4.2 depicted $Pd(3MeOS2M)_2$ graphs and 3D interactions maps, respectively. The MolDock score was -192.885 and the IC_{50} values were 7.617. Hydrogen bonds Asn 415, Ser 240 and Leu 313 were found in the enzyme's 3D interaction map $Pd(3MeOS2M)_2$. In Figure 4.2, the green lines in the figure depict hydrogen bonding.



Figure 4.2 The active region of α-glucosidase and $Pd(3MeOS2M)_2$ interact



Figure 4.3 $Pd(3MeOS2M_2)$ is the proportion of chemical activity $[Pd(3MeOS2M)_2]$ - $[Pd(3MeOS2M)_2]$ is the molecule diagram of the enzyme α-glucosidase

By inhibiting the α–glucosidase enzyme, this $Pd(4MeOS1M)_2$ molecule was shown to work. Figures 4.5 and Figure 4.4 depicted $Pd(4MeOS1M)_2$ graphs and 3D interactions maps, respectively. The MolDock score was -237.517 and the IC_{50} values were 0.436. Hydrogen bonds Arg 315, Thr 310, Ser 241 and Lys 156 were found in the enzyme's 3D interaction map $Pd(4MeOS1M)_2$. In Figure 4.4, the green lines in the figure depict hydrogen bonding.



Figure 4.4 The active region of α-glucosidase and $Pd(4MeOS1M)_2$ interact



Figure 4.5 $Pd(4MeOS1M)_2$ is the proportion of chemical activity $[Pd(4MeOS1M)_2]$ - $[Pd(4MeOS1M)_2]$ is the molecule diagram of the enzyme α-glucosidase

By inhibiting the α–glucosidase enzyme, this $Pd(4MeOS2M)_2$ molecule was shown to work. Figures 4.7 and Figure 4.6 depicted $Pd(4MeOS2M)_2$ graphs and 3D interactions maps, respectively. The MolDock score was -227.692 and the IC_{50} values were 6.301. Hydrogen bonds Ser 241, Ser 240 and Lys 156 were found in the enzyme's 3D interaction map $Pd(4MeOS2M)_2$. In Figure 4.6, the green lines in the figure depict hydrogen bonding.



Figure 4.6 The active region of α-glucosidase and $Pd(4MeOS2M)_2$ interact



Figure 4.7 $Pd(4MeOS2M)_2$ is the proportion of chemical activity $[Pd(4MeOS2M)_2]$ - $[Pd(4MeOS2M)_2]$ is the molecule diagram of the enzyme α-glucosidase

By inhibiting the α–glucosidase enzyme, this $Cu(3MeOS2M)_2$ molecule was shown to work. Figures 4.9 and Figure 4.8 depicted $Cu(3MeOS2M)_2$ graphs and 3D interactions maps, respectively. The MolDock score was -186.8 and the IC_{50} values were 0.358. Hydrogen bonds Gly 160 and Lys 156 were found in the enzyme's 3D interaction map $Cu(3MeOS2M)_2$. In Figure 4.8, the green lines in the figure depict hydrogen bonding.



Figure 4.8 The active region of α-glucosidase and $Cu(3MeOS2M)_2$ interact



Figure 4.9 $Cu(3MeOS2M)_2$ is the proportion of chemical activity $[Cu(3MeOS2M)_2]$ - $[Cu(3MeOS2M)_2]$ is the molecule diagram of the enzyme α-glucosidase

By inhibiting the α–glucosidase enzyme, this $Cu(4MeOS1M)_2$ molecule was shown to work. Figures 4.11 and Figure 4.10 depicted $Cu(4MeOS1M)_2$ graphs and 3D interactions maps, respectively. The MolDock score was -229.596 and the IC_{50} values were 0,517. Hydrogen bonds Thr 310, Gln 279 and Lys 156 were found in the enzyme's 3D interaction map $Cu(4MeOS1M)_2$. In Figure 4.10, the green lines in the figure depict hydrogen bonding.



Figure 4.10 The active region of α-glucosidase and $Cu(4MeOS1M)_2$ interact



Figure 4.11 $Cu(4MeOS1M)_2$ is the proportion of chemical activity $[Cu(4MeOS1M)_2]$ - $[Cu(4MeOS1M)_2]$ is the molecule diagram of the enzyme α-glucosidase

By inhibiting the α–glucosidase enzyme, this $Cu(4MeOS2M)_2$ molecule was shown to work. Figures 4.13 and Figure 4.12 depicted $Cu(4MeOS2M)_2$ graphs and 3D interactions maps, respectively. The MolDock score was -216.549 and the IC50 values were 0,300. Hydrogen bonds Thr 310, Gln 279 and Lys 156 were found in the enzyme's 3D interaction map $Cu(4MeOS2M)_2$. In Figure 4.12, the green lines in the figure depict hydrogen bonding.



Figure 4.12 The active region of α-glucosidase and $Cu(4MeOS2M)_2$ interact



Figure 4.13 $Cu(4MeOS2M)_2$ is the proportion of chemical activity $[Cu(4MeOS2M)_2]$ - $[Cu(4MeOS2M)_2]$ is the molecule diagram of the enzyme α-glucosidase

Strong compounds with appropriate IC_{50} values were chosen to dock with the α-glucosidase active residues. Molecular conformations 1 through 6 were selected for usage. Molecular docking experiments showed that each of the six powerful chemicals tested matched perfectly in the active area of -glucosidase. $Pd(3MeOS2M)_2$ with Asn 415, Ser 240, and Leu 313 in the cavity surrounding by $Pd(3MeOS2M)_2$ formed the strongest compound with three hydrogen bonds, with a scoring function of -192.885 and Three hydrogen bonds were created between $Cu(4MeOS2M)_2$ and three amino acids: Thr 310, Gln 279, and Lys 156 in the cavity around $Cu(4MeOS2M)_2$. In individuals with type 2 diabetes, a meta-analysis was done to investigate the effects of AGIs on glucose levels, insulin secretion, and body weight. Researchers found that AGIs (acarbose, voglibose, and miglitol) were more effective than placebo and other active oral hypoglycemic medications in Asian and Caucasian type 2 diabetes patients. In both Asian and Caucasian groups, AGIs treatment led to an increase in insulin levels. Clinical investigations spanning 12–52 weeks indicated that AGI treatment lowered HbA1c by an average of 0.50 percent and FPG by an average of 0.53 mmol/L on average in Asian patients compared to the placebo effect. Although HbA1c was lowered relative to active medications (primarily sulphonylurea), AGI therapy was not favored. Caucasians had similar reductions on HbA1c and FPG after correcting for placebo effect (0.68 percent and 0.88 mmol/L, respectively). Our meta-findings analysis's are in line with those of other studies, which focused mostly on Caucasians. It was found that acarbose and miglitol both reduced HbA1c by 77% and 68%, respectively, while

voglibose had a benefit of 47% (95 percent confidence interval 0.31–0.63), while voglibose had an effect of 47% (95 percent confidence interval 0.31–0.63). The results were compared to 36 clinical trials in Caucasians and five trials in Asian populations. The mean FPG drop after acarbose treatment is 1.09 mmol/l (28 comparisons; 95 percent CI 0.83–1.36), miglitol therapy is 0.52 mmol/l (two comparisons; 95 percent CI 0.16–0.88) and voglibose therapy is a 0.60 mmol/l (one comparison; 95 percent CI) after the removal of any placebo effects. It's also worth noting that the total HbA1c decrease of 0.38 percent (95 percent CI 20.02–0.77 percent) favors sulfonylurea therapy over acarbose, although this reduction is not statistically significant. acarbose was shown to be more successful than a placebo in lowering HbA1c and FPG levels after seven months of treatment, although the precise weighted mean difference was not provided by Derosa (Derosa and Maffioli 2012) in a comprehensive study (15 studies in Caucasians and 4 trials in Asians). AGI therapy reduced fasting insulin secretion in Asians by 0.78 uU/mL and by 0.55 uU/mL compared to placebo and active medications. An average of 1.24 uU/mL of fasting insulin was reduced in Caucasians with AGI treatment compared to placebo and active medicines. There were no significant differences in fasting insulin levels between Asian and Caucasian participants after AGI treatment. Caucasian subjects were found to be 40.8 pmol/l (95 percent CI 21.0–50.6) lower in 1-hour post-load insulin levels after treatment with acarbose than those who received a placebo, according to Van de Laar's research (Laar et al. 2005). Asian patients are not a reference group when it comes to systematic examination. Compared to either a placebo or an active medication, AGI therapy resulted in a 1.0 kg weight loss in Asians. In Caucasians, AGI treatment lowered body weight by 0.73 kg and 1.79 kg, respectively, when compared to a placebo and an active medication. After adjusting for the placebo effect, Asian and Caucasian weight gains were similarly significant. Findings made by us seem to be in conflict with previous research. It was shown that acarbose reduced BMI by 0.17 kg/m2, but not "body weight," in Van de Laar's study (Laar et al. 2005). Caucasians were the focus of his meta-analysis (36 trials in Caucasians and 5 trials in Asians). People with type 2 diabetes who follow an Eastern diet had lower HbA1c levels than those who follow a Western diet, according to a recent meta-analysis (Zhu et al. 2013). This is at odds with our meta-analysis. Using this information, researchers concluded that AGIs are more

effective in treating type 2 diabetes in eastern people. Because of publication bias and performance bias in many research on Eastern diets, this fascinating result should not be included in our meta-analysis. The meta-shortcomings analysis's must be acknowledged. Glycemic control in both the AGI and control groups was shown to be subpar in many investigations. In the included studies, the titration of hypoglycemic medicines was directed by different goals for HbA1c or FPG. Each study was unique in its approach, both in terms of its inclusion criteria and its origins. Studies that lasted less than a year focused on a few key clinical outcomes including cardiovascular events and deaths. There is also the possibility of prejudice in the reporting. To find out whether AGI therapy is effective and has any additional side effects than glucose intolerance in Asians, we combined the data of many studies and made comparisons between Asians and Caucasians in terms of these effects. Possibly the first systematic evaluation of AGI therapy in Asian and the first comparison of AGI treatment effectiveness between Asian and Caucasian populations. It is possible that the findings of this research might be used to produce guidelines for clinical practice and guideline development. According to this meta-analysis, the effectiveness of AGI therapy in Asians is equivalent to that in Caucasians in terms of lowering blood glucose, reducing body weight, and decreasing insulin production.

5. CONCLUSIONS AND RECOMMENDATION

Antihyperglycemic drugs (AGIs) are safe and effective. As a consequence, there is no increased risk of hypoglycemia with acarbose, miglitol, or voglibose. Cardiovascular risk factors have been reduced and the evolution of prediabetes into full-blown T2DM has been delayed. In diabetes mellitus type 2, α-glucosidase inhibitors are used to better manage hyperglycemia, especially postprandial hyperglycemia. With a proper diabetic diet and exercise, they may be used as monotherapy or in combination with other anti-diabetic medications. Docking with Sesamin and its derivatives is made possible by the stable structure. Conserved amino acids in α-Glucosidase play a vital role in maintaining the enzyme's functional conformation and are closely linked to donor substrate binding, as shown by docking findings Studying the domain-inhibitor interaction provided valuable insight into the putative binding mechanism of the domain and inhibitor. Hydrogen bonds are well-known to have a vital role in biological molecule structure and function.

REFERENCES

Anonymous. 1998a. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet., 352(9131): 854-865.

Anonymous. 1998b. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet., 352: 837–53.

Bayraktar, M., Thiel, D. H. and Adalar, N. 1996. A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients. Diabetes care., 19: 252–254.

Bischoff, H. 1995. The mechanism of alpha-glucosidase inhibition in the management of diabetes. Clinical and investigative medicine. Medecine clinique et experimentale., 18(4): 303-311.

Bolen, S., Wilson, L., Vassy, J., Feldman, L., Yeh, J., Marinopoulos, S., and Bass, E. 2007. Comparative effectiveness and safety of oral diabetes medications for adults with type 2 diabetes. Science., 3: 17-20.

Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, and Cheng, A. Y. 2013. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. Canadian journal of diabetes., 37: 1–3.

Cheng, A. Y. and Fantus, I. G. 2005. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ: Canadian Medical Association journal., 172: 213–226.

Chiasson, J. L., Josse, R. G. and Gomis, R. 2003. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA., 290: 486–94.

Chiasson, J. L., Josse, R. G., Gomis, R. F., Hanefeld, M., Karasik, A., and Laakso, M. 2004. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia., 47(6): 969-975.

Chiniwala, N. and Jabbour, S. 2011. Management of diabetes mellitus in the elderly. Current opinion in endocrinology, diabetes, and obesity., 18: 148–152.

Coniff, R. F., Shapiro, J. A., Seaton, T. B., and Bray, G. A. 1995. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. The American journal of medicine., 98(5): 443-451.

Derosa, G., and Maffioli, P. 2012. Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review. Clinical therapeutics., 34(6): 1221-1236.

Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., ... and PROactive Investigators. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. The Lancet., 366(9493): 1279-1289.

Fujita H, Yamagamu T, Ahshima K. 2001. Long-term ingestion of a fermented soybean-derived Touchi-extract with alpha-glucosidase inhibitory activity is safe and effective in humans with borderline and mild type-2 diabetes. J Nutr., 131: 2105–8.

Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., Davidson, M. B., Einhorn, D., Garvey, W. T., Grunberger, G., Handelsman, Y., Hirsch, I. B., Jellinger, P. S., McGill, J. B., Mechanick, J. I., Rosenblit, P. D., Umpierrez, G. E. and Davidson, M. H. 2013. American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists., 19: 536–557.

Gerstein, H. C., Yusuf, S. and Bosch, J. 2006. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet., 368: 1096–105.

Goldner, M. G., Knatterud, G. L. and Prout, T. E. 1971. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA., 218: 10–14.

Gourgari, E., Wilhelm, E. E., Hassanzadeh, H., Aroda, V. R., and Shoulson, I. 2017. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data. Journal of Diabetes and its Complications., 31(12): 1719-1727.

Hakamata, W., Kurihara, M., Okuda, H., Nishio, T. and Oku, T. 2009. Design and Screening Strategies for alpha-Glucosidase Inhibitors Based on Enzymological Information. Current Topics in Medicinal Chemistry., 9: 3–12.

Hanefeld, M. and Schaper, F. 2007. The role of alpha-glucosidase inhibitors (acarbose). In Pharmacotherapy of diabetes: New developments, pp. 143-152, Springer, Boston, MA.

Hanefeld, M. G. 2004. Meta-analysis of long-term studies to assess the effect of acarbose on cardiovascular risk reduction-scientifically credible: Reply. European heart journal., 25(13): 1179-a.

Hedrington, M. S. and Davis, S. N. 2019. Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes. Expert opinion on pharmacotherapy., 20: 2229–2235.

Hoffmann, J. 1997. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. The American journal of medicine., 103(6): 483-490.

Holman, R. R., Cull, C. A., and Turner, R. C. 1999. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes care., 22(6): 960-964.

Inzucchi S. E. 2002. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA., 287: 360–372.

Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R. and Matthews, D. R. 2012. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia., 55: 1577–1596.

Johansen, K. 1999. Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes care., 22(1): 33-37.

Joshi, S. R., Standl, E., Tong, N., Shah, P., Kalra, S. and Rathod, R. 2015. Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. Expert opinion on pharmacotherapy., 16: 1959-1981.

Joubert, P. H., Venter, H. L. and Foukaridis, G. 1990. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism? British journal of clinical pharmacology., 30: 391-396.

Junge B, M. M. 1996. Chemistry and structure–activity relationships of glucosidase inhibitors, In I. J. (Eds.), and P. W. Kuhlmann J (Ed.), Handbook of Experimental Pharmacology, pp. 411-482, Springer Science and Business Media.

Kado, S., Murakami, T., Aoki, A., Nagase, T., Katsura, Y., Noritake, M., ... and Nagata, N. 1998. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diabetes research and clinical practice., 41(1): 49-55.

Kaiser, T., and Sawicki, P. T. 2004. Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data. Diabetologia., 47(3): 575-580.

Laar, F. A. 2008. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vascular health and risk management., 4(6): 1189.

Laar, F. A., and Lucassen, P. L. 2004. No evidence for a reduction of myocardial infarctions by acarbose. European heart journal., 25(13): 1179-1179..

Laar, F. A., Lucassen, P. L., Akkermans, R. P., Van De Lisdonk, E. H., Rutten, G. E., and Van Weel, C. 2005. α-Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes care., 28(1): 154-163..

Laube, H., Linn, T. H., and Heyen, P. 1998. The effect of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Experimental and clinical endocrinology and diabetes., 106(03): 231-233.

Lebovitz, H. E. 1997. Alpha-glucosidase inhibitors. Endocrinology and metabolism clinics of North America., 26(3): 539-551..

Li, Y., Tong, Y., Zhang, Y., Huang, L., Wu, T., and Tong, N. 2014. Acarbose monotherapy and weight loss in Eastern and Western populations with

hyperglycaemia: an ethnicity-specific meta-analysis. International journal of clinical practice., 68(11): 1318-1332.

Liu, M., Zhang, W., Wei, J., and Lin, X. 2011. Synthesis and α-glucosidase inhibitory mechanisms of bis (2, 3-dibromo-4, 5-dihydroxybenzyl) ether, a potential marine bromophenol α-glucosidase inhibitor. Marine drugs., 9(9): 1554-1565.

Manohar, V., Talpur, N. A., Echard, B. W., Lieberman, S., and Preuss, H. G. 2002. Effects of a water-soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice. Diabetes, Obesity and Metabolism., 4(1): 43-48.

Matsumura, M., Monden, T., Miyashita, Y., Kawagoe, Y., Shimizu, H., Nakatani, Y., ... and Kasai, K. 2009. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Advances in therapy., 26(6): 660-666.

Mertes, G. 2001. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from a 5-year surveillance study. Diabetes research and clinical practice., 52(3): 193-204.

Metzl, J. M., and Herzig, R. M. 2007. Medicalisation in the 21st century: Introduction. The Lancet., 9562(369): 697-698..

Monnier, L. and Colette, C. 2009. Target for glycemic control: concentrating on glucose. Diabetes care., 32: S199–S204.

Narita, T., Katsuura, Y., Sato, T., Hosoba, M., Fujita, H., Morii, T., and Yamada, Y. 2009. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabetic Medicine., 26(2): 187-188.

Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., and Zinman, B. 2006. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia., 49(8): 1711-1721.

Ning, F., Tuomilehto, J., Pyörälä, K., Onat, A., Söderberg, S., Qiao, Q., and DECODE Study Group. 2010. Cardiovascular disease mortality in Europeans in relation to fasting and 2-h plasma glucose levels within a normoglycemic range. Diabetes care., 33(10): 2211-2216.

Nissen, S. E., and Wolski, K. 2007. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine., 356(24): 2457-2471.

Pan, C. Y., Gao, Y., Li, G. W., Zhu, X. X., Gao, X., and Liu, X. 2009. A comparison of efficacy and tolerance of nateglinide and acarbose monotherapy in type 2 diabetes mellitus. Zhonghua nei ke za zhi., 48(4): 304-307.

Philip, E., Sundaram, M. L., Das, R., Chauhan, S. K., Deshpande, S., Ambhore, S., ... and Manjrekar, P. 2013. Acarbose improves glycemic control as add-on or monotherapy in Indian type-2 diabetes: Findings from the GlucoVIP multinational observational study. Indian Journal of Endocrinology and Metabolism., 17(3): S674.

Rahim, F., Zaman, K., Taha, M., Ullah, H., Ghufran, M., Wadood, A., Rehman, W., Uddin, N., Shah, S., Sajid, M., Nawaz, F. and Khan, K. M. 2020. Synthesis, in vitro alpha-glucosidase inhibitory potential of benzimidazole bearing bis-Schiff bases and their molecular docking study. Bioorganic chemistry., 94: 103394.

Ratner, R., Goldberg, R. and Haffner, S. 2005. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care., 28: 88–94.

Reaven, G. M., Lardinois, C. K., Greenfield, M. S., Schwartz, H. C., and Vreman, H. J. 1990. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care., 13(3): 32-36.

Rosak, C., Haupt, E., Walter, T., and Werner, J. 2002. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. Diabetes, nutrition and metabolism., 15(3): 143-151.

Rutten, G. E. H. M., Grauw, W. J. C. and Nijpels, G. 2006. Dutch College of General Practitioners: guidelines on Type 2 diabetes, second revision (in Dutch). Huisarts Wet., 49: 37–52.

Scheen, A. J. 1998. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Diabetes and metabolism., 24(4): 311-320.

Scott, L. J. and Spencer, C. M. 2000. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs., 59: 521–549.

Sochacka, J. 2014. Docking of thiopurine derivatives to human serum albumin and binding site analysis with Molegro Virtual Docker. Acta Pol. Pharm., 71: 343-349.

Sochacka, J., and Baran, W. 2012. The investigation of the binding of 6-mercaptopurine to site I on human serum albumin. The Protein Journal., 31(8): 689-702.

Spiller, H. A. and Sawyer, T. S. 2006. Toxicology of oral antidiabetic medications. American journal of health-system pharmacy., 63: 929-938.

Standl, E. and Schnell, O. 2012. Alpha-glucosidase inhibitors 2012–cardiovascular considerations and trial evaluation. Diabetes and Vascular Disease Research., 9: 163-169.

Stein, S. A., Lamos, E. M. and Davis, S. N. 2013. A review of the efficacy and safety of oral antidiabetic drugs. Expert opinion on drug safety., 12: 153–175.

Takahara, M., Shiraiwa, T., Katakami, N., Kaneto, H., Matsuoka, T. A., and Shimomura, I. 2014. Efficacy of adding once-and thrice-daily voglibose in Japanese type 2 diabetic patients treated with alogliptin. Endocrine Journal., 61(5): 447-456.

Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., ... and Uusitupa, M. 2001. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine., 344(18): 1343-1350.

Vega, J., Crespo, M., Escudero, J. M., Sanchez, L. and Rivas, L. L. 2000. Acarbose-induced acute hepatitis. Report of two events in the same patient. Gastroenterologia y hepatologia., 23: 282-284.

Vichayanrat, A., Ploybutr, S., Tunlakit, M., and Watanakejorn, P. 2002. Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Research and Clinical Practice., 55(2): 99-103.

Weng, J., Soegondo, S., Schnell, O., Sheu, W. H. H., Grzeszczak, W., Watada, H., ... and Kalra, S. 2015. Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database. Diabetes/metabolism research and reviews., 31(2): 155-167.

Williams, R., Rapport, F., Elwyn, G., Lloyd, B., Rance, J., and Belcher, S. 2004. The prevention of type 2 diabetes: general practitioner and practice nurse opinions. British journal of general practice., 54(504): 531-535.

Yang, W., Liu, J., Shan, Z., Tian, H., Zhou, Z., Ji, Q., ... and Chen, W. 2014. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. The Lancet Diabetes and Endocrinology., 2(1): 46-55.

Zheng, M. Y., Yang, J. H., Shan, C. Y., Zhou, H. T., Xu, Y. G., Wang, Y., ... and Chen, L. M. 2013. Effects of 24-week treatment with acarbose on glucagon-like peptide 1 in newly diagnosed type 2 diabetic patients: a preliminary report. Cardiovascular diabetology., 12(1): 1-8.

Zhu, Q., Tong, Y., Wu, T., Li, J., and Tong, N. 2013. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an Eastern or Western diet: a systematic meta-analysis. Clinical therapeutics., 35(6): 880-899.

CURRICULUM VITAE

Personal Information

Name and Surname : Ayoob Hasan Jwair JWAIR

Education

MSc	Çankırı Karatekin University Graduate School of Natural and Applied Sciences Department of Chemistry	2020-Present
Undergraduate	Baghdad University Faculty of Sciences Department of Chemistry	2003-2009

Work Experience

Year	**Institution**	**Position**
2011-Present	Presidency of Dewan Al-Waqf Alsonny, Directorate of Religious Education and Islamic Studies	Teacher